Publicado ennews/estado, Noticia Local

Positive Early Study Results Help Pave Wave for Titan Pharmaceuticals to Move Forward with its JT-09 ProNeura Development Program

SOUTH SAN FRANCISCO, Calif., Feb. 1, 2021 /PRNewswire/ — Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that studies of its kappa opioid agonist peptide, JT-09, has demonstrated high potency and specificity for the human kappa-opioid receptor («KOR»). JT-09 is being developed for use in combination with Titan’s ProNeura® long-term, continuous drug delivery technology for the treatment […]